TITLE

Schwarz Pharma Acquires Rights to Drug for Epilepsy

PUB. DATE
February 2000
SOURCE
Worldwide Biotech;Feb2000, Vol. 12 Issue 2, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the rights acquired by Schwarz Pharma to complete the development and commercialization of Harkoseride, a novel drug in the area of central nervous system disease.
ACCESSION #
2766905

 

Related Articles

  • COMPANY SPOTLIGHT -- Schwarz Pharma.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p19 

    The article features Schwarz Pharma, a company engaged in research and development, production, marketing, and distribution of pharmaceutical products. It has a drug development team engaged in developing drugs for the treatment of neurological and urological disorders. The company's products...

  • Schwarz: lacosamide on track for dual approval.  // PharmaWatch: CNS;January 2005, Vol. 4 Issue 1, p4 

    Comments on the results of Schwarz Pharma AG's phase IIb lacosamide trial. Efficacy of oral lacosamide as an epileptic drug; Schedule on the global launch of the drug; Growth in the anticonvulsant market.

  • Moexipril gets June launch.  // Drug Topics;5/22/95, Vol. 139 Issue 10, p8 

    Reports on Schwarz Pharma's launching of Univasc or moexipril in June 1995. Drug as the tenth ACE inhibitor to enter the United States market.

  • Schwarz paying for switches.  // Drug Topics;1/24/94, Vol. 138 Issue 2, p6 

    Reports on Schwarz Pharma's offer of five dollars to pharmacists who convince patients and their doctors to switch a prescription for isosorbide mononitrate, Wyeth-Ayerst, Laboratories (Ismo), to Schwarz's generic version of the drug, Monoket.

  • Generic firm offers incentive for switch hitters. Muirhead, Greg // Drug Topics;2/7/94, Vol. 138 Issue 3, p94 

    Reports on generic drugs manufacturer Schwarz Pharma's payment of pharmacists who convince patients and their doctors to switch a prescription to the company's drug. Advantages of the program; Contact information.

  • Income to soar for Schwarz.  // European Chemical News;2/24/2003, Vol. 78 Issue 2041, p9 

    Presents a forecast on the net income of Schwarz Pharma in 2003. Sales outlook; Factors that would influence the income of Schwarz.

  • Schwarz Pharma stays positive.  // Life Science Today;Dec2000, Vol. 1 Issue 6, p6 

    Reports on the decline of the profits earned by Schwarz Pharma in Germany.

  • New packaging.  // Drug Topics;4/19/99, Vol. 143 Issue 8, p115 

    Informs about the latest packaging of Schwarz Pharma Inc.'s Colyte, an oral solution for cleansing the bowel before colonoscopy or barium enema X-ray examination.

  • DTC coming for Verelan? Dickinson, James G. // Medical Marketing & Media;May99, Vol. 34 Issue 5, p36 

    Reports on Schwarz Pharma's consideration of launching a direct-to-consumer campaign as part of the product launch of Verelan PM (verapamil hydrochloride), a calcium channel blocker.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics